Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma

Launched by FENGYAN JIN · Apr 23, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with primary central nervous system lymphoma (PCNSL), a type of cancer that occurs in the brain and spinal cord. The study aims to evaluate the safety and effectiveness of a combination of medications—rituximab, methotrexate, and thiotepa for the initial treatment, followed by etoposide and cytarabine to help keep the cancer from coming back. Researchers hope that this new regimen will not only improve the chances of remission, which is when the cancer is no longer detectable, but also extend the time patients can live without the disease, especially in younger individuals.

To participate in this trial, patients should be 60 years old or younger and have a confirmed diagnosis of diffuse large B-cell lymphoma specifically in the central nervous system, without having received any prior treatment. Participants will undergo a thorough examination to ensure they do not have other active cancers or serious health issues that could complicate their treatment. Those who join the study will receive the new treatment regimen and be closely monitored for its effects. This trial is currently recruiting participants, and involvement is entirely voluntary with informed consent required.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≤ 60 years, male or female
• • Histologically and immunohistochemically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) without prior treatment
• • No evidence of systemic lymphatic or hematopoietic involvement or other systemic disease, based on thorough physical examination and imaging/laboratory tests
• • Diagnosis meets criteria for Primary Central Nervous System Lymphoma (PCNSL)
• • Written informed consent obtained from the patient or their legal guardian
• • Voluntary agreement to participate in the study
• Exclusion Criteria:
• • Presence of another active malignancy
• • Known history of HIV infection or diagnosis of acquired immunodeficiency syndrome (AIDS)
• • Known allergy to any of the investigational drugs or their excipients
• * Any condition that, in the opinion of the investigator, may lead to early study termination, including but not limited to:
• • Severe comorbidities
• • Significant laboratory abnormalities
• • Serious social or family circumstances affecting safety or compliance